Bicara Therapeutics Inc. BCAX
8.77 USD -0.19 (-2.12%)
Nov 4, 2026, 1:31 PM EST
8.69 Day range 9.28
7.87 52-week range 30.99
- YTD
- -47.89%
- 1 year
- -40.50%
Financial health
Altman Z-Score
6.80 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 5
- P/E 1
- P/B 2
Valuation
P/E -6.7×
FY 2022 5y median -18.7× FY 2025
P/S 0.0×
FY 2022 5y median 0.0× FY 2025
P/B 2.3×
FY 2022 5y median 2.1× FY 2025
P/FCF -8.6×
FY 2022 5y median -19.4× FY 2025
EV/EBITDA -6.0×
FY 2022 5y median -12.8× FY 2025
EV/Sales 0.0×
FY 2022 5y median 0.0× FY 2025
FCF Yield -11.6%
FY 2022 5y median -5.9% FY 2025
Profitability
Gross Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2022 5y median 0.0% FY 2025
ROE -34.4%
FY 2022 5y median -18.8% FY 2025
ROIC -38.6%
FY 2022 5y median -16.6% FY 2025
ROA -32.0%
FY 2022 5y median -27.1% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2022 FY 2025
Operating Income -88.9%
FY 2022 FY 2025
EPS (diluted) -101.6%
FY 2022 FY 2025
Free Cash Flow -43.2%
FY 2022 FY 2025
Financial Health
Current Ratio 14.6×
FY 2022 5y median 14.9× FY 2025
Quick Ratio 14.6×
FY 2022 5y median 14.9× FY 2025
Debt / Equity 0.0×
FY 2022 5y median 0.0× FY 2025
Net Debt / EBITDA 0.7×
FY 2022 5y median 2.6× FY 2025
Interest Coverage 0.0×
FY 2022 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2022 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2022 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31